Drug safety evaluation of vemurafenib in the treatment of melanoma

Author： Tsai Kenneth Y   Nowroozi Sasan   Kim Kevin B  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.12, Iss.5, 2013-09, pp. : 767-775

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vemurafenib for the treatment of melanoma

By Jordan Emmet John   Kelly Catherine M  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 17, 2012-12 ,pp. : 2533-2543

Informa Healthcare

Access to resources Recommend Favorite

Vemurafenib: Development of resistance during treatment for malignant melanoma: case report

By  

Reactions Weekly, Vol. 1, Iss. 1373, 2011-01 ,pp. : 30-31

Adis International

Access to resources Recommend Favorite

Drug safety evaluation of zonisamide for the treatment of epilepsy

By Zaccara Gaetano   Tramacere Luciana   Cincotta Massimo  

Expert Opinion on Drug Safety, Vol. 10, Iss. 4, 2011-07 ,pp. : 623-631

Informa Healthcare

Access to resources Recommend Favorite

Drug safety evaluation of naltrexone/bupropion for the treatment of obesity

By Verpeut Jessica L   Bello Nicholas T  

Expert Opinion on Drug Safety, Vol. 13, Iss. 6, 2014-06 ,pp. : 831-841

Informa Healthcare

Access to resources Recommend Favorite

Vemurafenib: Targeted Inhibition of Mutated BRAF for Treatment of Advanced Melanoma and Its Potential in Other Malignancies

By Sharma Anant   Shah Sachin R.   Illum Henrik   Dowell Jonathan  

Drugs, Vol. 72, Iss. 17, 2012-12 ,pp. : 2207-2222

Adis International

Access to resources Recommend Favorite